89Zr-desferrioxamine B-7E11 displays high tumor-to-background tissue contrast in immuno-PET and can be used as a tool to monitor and quantify with high specificity tumor response in prostate-specific membrane antigen (PSMA)-positive prostate cancer, according to research published in the October issue of the Journal of Nuclear Medicine.
MD Anderson Cancer Center in Houston has initiated orders of Cesium-131 brachytherapy seeds from IsoRay, as it continues its clinical research study investigating brachytherapy's ability to help control intermediate risk prostate cancer, which is a classification of early stage prostate cancer that has shown a tendency to recur following standard treatment.
The Molecular Imaging Biomarker Research Group of Siemens Medical Solutions USA has completed a Phase II multicenter clinical trial of its HX4 positron PET imaging biomarker, which is designed to detect hypoxia—a reduction in tissue oxygen levels—in solid tumors.
Written by James Brice
Slowly but steadily, radiation oncologists are adopting PET and PET/CT to measure the early response of cancers to radiotherapy and other treatments. And progress has been significant.
A combination of well-known safety procedures could prevent most patient-harming errors in radiation therapy, according to a study presented at the annual meeting of the American Association of Physicists in Medicine (AAPM) and Canadian Organization of Medical Physicists, July 31 to Aug. 4 in Vancouver, Canada.
Molecular radiotherapy needs an injection of research and funding to broaden its usage and expand its effectiveness as a minimally invasive method of cancer treatment, according to an April report released by the British Institute of Radiology (BIR).
Folate-targeted nanoparticle Paclitaxel Y90 is a biologically-targeted chemoradiotherapy for ovarian cancer and represents a potential novel treatment for ovarian peritoneal metastases, according to a presentation at the annual meeting of the American Association for Cancer Research (AACR) last week in Orlando, Fla.
Written by Manjula Puthenedam, PhD
PET imaging is effective in staging, restaging, detecting recurrence and treatment monitoring across a wide range of cancers. This feature discusses updates on important PET imaging clinical trials in cancer care by the American College of Radiology Imaging Network and National Cancer Institute and focuses on improving cancer staging and predicting response to therapy. The National Oncology PET Registry (NOPR) recently published the results of the impact of dedicated brain PET on intended patient management and opened a registry for 18F-sodium fluoride PET to identify bone metastasis. The Cancer and Leukemia Group B (CALGB) sponsored by the NCI is another group conducting clinical trials in cancer, yet PET trials are still few.
Regional and local characterization of 18F-FDG PET tracer heterogeneity in tumors are more powerful than global measurements currently used in clinical practice, which means they could hold "the potential to revolutionize the predictive role of PET in cancer treatment,” according to research published in the March issue of the
Journal of Nuclear Medicine.
RSS 
